We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2025
 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Diagnostics

Image: A micrograph of urothelial carcinoma of the urinary bladder (Photo courtesy of Baylor College of Medicine).

Clinical Trial Highlights Poor Prognosis for Bladder Cancer Patients

Analysis of the IMvigor 210 clinical trials involving patients with platinum-refractory or cisplatin-ineligible urothelial carcinoma (the most common type of bladder cancer) who were treated with the PD-L1 inhibitor atezolizumab identified a resistance signature as an immune biomarker that may aid in development of personalized treatment of the disease. More...
20 May 2019
Image: (A) Low magnification view of cancer nodule with the central tumor bulk consisting predominantly of invasive cribriform Gleason pattern four. (B) Low magnification view of the same cancer nodule with an outer rim of accentuated syntaphilin (SNPH) staining. The invasive front is defined as the external rim of each cancer nodule abutting the adjacent stroma as outlined in this image as the zone between the dotted and solid lines. Arrows denote accentuated SNPH staining at the tumor-stromal interface (Photo courtesy of the American Journal of Pathology).

Prostate Cancer Severity Indicated by Location and Concentration of Syntaphilin

A biomarker has been identified that may enable doctors to predict which patients with early indications of prostate cancer will be likely to develop the much more serious invasive and metastatic form of the disease. More...
20 May 2019

Clinical Validation Bolsters Liquid Biopsy Evidence Base

Non–small-cell lung cancer (NSCLC) accounts for more than 85% of lung cancer – the majority of patients who present have advanced-stage disease and are treated with systemic therapies. More...
15 May 2019
Image: The RealTime HBV is an in vitro polymerase chain reaction (PCR) assay for the quantitation of Hepatitis B Virus (HBV) DNA in human plasma or serum from HBV-infected individuals (Photo courtesy of Abbott Molecular).

Serum HBV RNA Quantification Monitors Chronic Hepatitis B Infection

Chronic hepatitis B viral infection is a global health problem, especially in the Asian-Pacific region. Approximately 1.2 million people in the USA and 350 million people worldwide have Hepatitis B. and about 650,000 people die annually from HBV infection related liver failure, liver cirrhosis and liver cancer. More...
15 May 2019
Image: EndoPredict is a second-generation breast cancer recurrence test for highly accurate assessment of 10-year risk of distant recurrence (Photo courtesy of Myriad Genetics).

Breast Cancer Test Determines Most Effective Treatment

For the clinical management of patients with estrogen receptor (ER)-positive breast cancer, several clinico-pathological and molecular characteristics of the tumor have to be considered for prognosis and treatment decisions. More...
14 May 2019
Image: The RealTime High-Risk HPV assay is designed for the detection of high-risk HPV genotypes in cervical specimens from women with precancerous lesions of the cervix uteri (≥ CIN2) and cervical cancer to provide clinically meaningful results in cervical cancer screening (Photo courtesy of Abbott Molecular).

Urine Test Could Prevent Cervical Cancer

The strategy of cervical screening depends on reducing the incidence of cervical cancer through the detection and treatment of its precursor lesion, high-grade cervical intraepithelial neoplasia (CIN2+). More...
14 May 2019
Image: A photomicrograph showing tumor-infiltrating lymphocytes in a case of colorectal cancer with evidence of high microsatellite instability (MSI-H) on immunostaining (Photo courtesy of Nephron).

Biomarker Predicts Appropriate Immunotherapy for Cancer Patients

Microsatellite instability (MSI) is a hypermutable phenotype caused by the loss of DNA mismatch repair activity. MSI is detected in about 15% of all colorectal cancers; 3% are of these are associated with Lynch syndrome. MSI is a biomarker for response to immune checkpoint inhibitors (ICPIs). More...
14 May 2019
Visit expo >
Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Gold Member
Hybrid Pipette
SWITCH
Human Estradiol Assay
Human Estradiol CLIA Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay

In Other News



Genetic Testing channel of LabMedica brings the latest in molecular genetics, cytogenetics, and epigenetics, and methods from PCR to FISH, and more.
Copyright © 2000 - 2025 Globetech Media.
All rights reserved.
GLOBE SCIENTIFIC, LLC